Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia
Mené sur 38 patients atteints d'une leucémie lymphoïde aiguë Ph- récemment diagnostiquée (âge médian : 37 ans), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans récidive, et la toxicité d'un traitement de première ligne combinant chimiothérapie intensive (de type hyper-CVAD) et blinatumomab dispensé de façon séquentielle
Blinatumomab, a CD19/CD3 bispecific T-cell engager active as monotherapy in relapsedor refractory B-cell acute lymphocytic leukaemia, was approved for adults with positiveminimal residual disease (MRD) in Europe and the USA in 2018. Approval was grantedon the basis of a single-arm, phase 2 study, in which 78% of included patients hadan MRD-negative complete response and promising outcomes and acceptable toxicity wereseen. Early experiences have also been encouraging with blinatumomab as first-line treatmentof Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphocytic leukaemiain older adults (aged >65 years)—a population that has previously had poor outcomesowing to adverse biology and poor tolerance to chemotherapy.
The Lancet Haematology , commentaire, 2021